Related Experiment Video
Updated: Feb 9, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.6K
Chemotherapy-Induced Takotsubo Syndrome
Monika Budnik1, Jakub Kucharz2, Paweł Wiechno3
1First Department of Cardiology, Warsaw Medical University, Warsaw, Poland.
Advances in Experimental Medicine and Biology
|June 10, 2018
Summary
Takotsubo syndrome, a heart condition mimicking heart attacks, is an underdiagnosed complication in cancer patients undergoing systemic treatment. Early diagnosis and specific management are crucial to prevent fatal outcomes like cardiac arrest.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Systemic cancer treatments can lead to significant cardiovascular complications.
- Takotsubo cardiomyopathy (Takotsubo syndrome) is a transient heart dysfunction that mimics acute coronary syndrome but lacks coronary artery changes.
- This syndrome is an underrecognized complication of oncological treatment.
Purpose of the Study:
- To review case reports of Takotsubo syndrome in cancer patients following systemic therapy.
- To analyze diagnostic findings and emphasize the importance of recognizing this complication.
Main Methods:
- Systematic review of the Medline database for case reports.
- Inclusion of all types of anticancer drugs.
- Review of electrocardiography, echocardiography, coronary angiography, troponin levels, myocardial necrosis markers, and natriuretic peptides.
Main Results:
- Takotsubo syndrome is an underdiagnosed complication in cancer patients receiving systemic therapy.
- The syndrome can lead to severe outcomes, including cardiogenic shock and cardiac arrest.
- Specific diagnostic procedures are necessary for timely identification.
Conclusions:
- Takotsubo syndrome should be considered in cancer patients presenting with chest pain or dyspnea during or after treatment.
- Prompt diagnosis and a tailored therapeutic approach are essential.
- Echocardiography and cardiac biomarker assessment are key diagnostic tools.
More Related Videos
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
793
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
793
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
908
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
908
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
690
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
690
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
628
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
628
01:24Nephrotic Syndrome I : Introduction
661
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
661
01:30Acute Coronary Syndrome I: Introduction
1.0K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.0K